March Therapeutics utilizes proprietary molecular recording technologies and advanced computing to map protein sequences to their functions, enabling high-throughput exploration of enzymatic landscapes. This approach addresses the challenge of efficiently harnessing nature's biomolecular machines for the development of targeted genetic therapies.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Harnessing nature's biomolecular machines for genetic medicine development is limited by the lack of a high-throughput approach to map protein sequences to their functions. Exploring enzymatic landscapes at scale remains a challenge due to difficulties in efficiently connecting genotypes to phenotypes.
Solution
March Therapeutics employs Biomolecular Learning, integrating molecular recording technologies and advanced computing, to map protein sequences to their functions. This approach enables high-throughput exploration of enzymatic landscapes and facilitates the discovery of novel genetic medicines. By converting biomolecular activities into sequence-based datasets, MarchTx gains a holistic view of protein function. AI/ML algorithms further process these datasets to accelerate the development of therapeutic modalities with desired properties, emulating natural evolutionary processes in a focused manner.
Target Audience
The primary focus is on researchers and developers in the field of genetic medicine seeking to efficiently discover and develop novel therapies.
Features
- Proprietary molecular recording technologies for ultra-high-throughput mapping of protein sequence to function
- AI/ML-driven analysis of sequence-based datasets to identify and optimize therapeutic modalities
- Ability to visualize the protein function landscape and emulate natural evolutionary processes